Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,710,779 | 1,657,250 | 1,490,249 | 1,113,685 | 1,019,654 |
| Marketable Securities | 1,298,444 | 1,251,234 | 1,234,375 | 1,743,900 | 1,612,568 |
| Receivables | 883,957 | 777,567 | 964,768 | 567,112 | 418,035 |
| Inventories | 84,025 | 82,719 | 75,383 | 71,688 | 65,581 |
| TOTAL | $4,219,308 | $4,050,662 | $3,952,811 | $3,643,699 | $3,268,258 |
| Non-Current Assets | |||||
| PPE Net | 518,257 | 513,147 | 501,754 | 499,791 | 498,684 |
| Investments And Advances | 22,170 | 22,170 | 51,314 | 68,593 | 68,592 |
| Other Non-Current Assets | 369,812 | 380,352 | 345,783 | 353,936 | 378,277 |
| TOTAL | $910,239 | $915,669 | $898,851 | $922,320 | $945,553 |
| Total Assets | $5,129,547 | $4,966,331 | $4,851,662 | $4,566,019 | $4,213,811 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 126,628 | 115,721 | 117,591 | 102,393 | 97,399 |
| Accrued Expenses | 946,485 | 1,080,197 | 1,153,648 | 918,966 | 704,165 |
| Other current liabilities | 227,488 | 220,068 | 236,942 | 218,311 | 199,888 |
| TOTAL | $1,349,475 | $1,466,349 | $1,555,477 | $1,300,847 | $1,075,623 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 3,213 | 4,845 | 2,541 | 15,080 | 28,160 |
| Other Non-Current Liabilities | 2,704,692 | 2,710,806 | 3,062,291 | 3,014,581 | 3,022,753 |
| TOTAL | $2,704,692 | $2,710,806 | $3,062,291 | $3,014,581 | $3,022,753 |
| Total Liabilities | $4,054,167 | $4,177,155 | $4,617,768 | $4,315,428 | $4,098,376 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 133,513 | 132,623 | 132,114 | 131,079 | 130,388 |
| Common Shares | 1,334 | 1,324 | 1,318 | 1,310 | 1,303 |
| Retained earnings | -6,496,533 | -6,702,524 | -7,160,420 | -7,411,504 | -7,345,227 |
| Other shareholders' equity | -24,894 | -20,097 | -21,775 | -29,952 | -37,517 |
| TOTAL | $1,075,380 | $789,176 | $233,894 | $250,591 | $115,435 |
| Total Liabilities And Equity | $5,129,547 | $4,966,331 | $4,851,662 | $4,566,019 | $4,213,811 |